Licensing CHOSOURCE™ mammalian expression platform for accelerating cell line development
The story
Celonic’s roots trace back to 1982 as a spin-off of the Max Planck Institute in Germany. They’re a “Pure Play” Biologics Contract Development Manufacturing Organization (CDMO) with significant expertise in the development and manufacturing of CHO-based monoclonal antibodies and other molecules.
For nearly 10 years, Celonic have been offering their in-house CHOvolution Chinese Hamster Ovary (CHO-K1) cell line as part of their services to develop and manufacture monoclonal antibodies and complex molecules. On April 8th, 2024 Celonic announced that they have made the strategic decision to replace their current CHOvolution® cell line with Revvity’s CHOSOURCE™ expression platform for all their antibody and complex molecule development and manufacturing. Dr. Samanta Cimitan, CEO of Celonic Group, commented “We are delighted to partner with Revvity to provide our customers a state-of-the-art GS expression platform with a track record of success which complements Celonic’s early phase offering. We are committed to bringing our customers of all sizes, expertise, agility, and solutions to develop and manufacture life-improving drugs effectively and efficiently.”
The transition to an established for cGMP manufacturing CHO cell line with GS (Glutamine Synthetase) selection system represents a significant advancement as this edited cell line is considered industry standard due to its ability to produce high yields of quality therapeutic proteins. The GS selection system is particularly advantageous because it allows for the efficient isolation of high-producing stable clones, which is crucial for the consistent production of biologics such as monoclonal antibodies. Celonic's decision to pivot their model and integrate their expertise with this advanced cell line demonstrates a commitment to innovation and quality in biopharmaceutical manufacturing.
Benefits of CHOSOURCE™ expression platform
The CHOSOURCE expression platform leverages Revvity’s gene-edited Glutamine Synthetase (“GS”) knockout CHO-K1 cGMP-compliant cell line and the CHOSOURCE TnT expression vector based on transposon technology. By Celonic making the switch they benefit from accelerated cell line development timelines through highly efficient cell line screening, reduction in selection times, and supports high reproducibility and stability across pools and clones.
Revvity’s bioproduction service
Revvity's Bioproduction unit is dedicated to empowering businesses across the global biotherapeutic landscape. With over 100 global licensees, ranging from academia to large pharma and biotech, as well as small to large CDMOs, we serve as the catalyst, helping our diverse partners to unlock their full potential. Our solutions are tailored to meet the unique needs of each customer, offering licensing terms fitted to their requirements.
Our commitment extends beyond mere numbers. Revvity's dedication to supporting both existing and new customers mirrors its approach exemplified in the partnership with Celonic. We are committed to driving innovation and scientific breakthroughs while delivering world-class solutions, forging a path toward advancements in the biotherapeutic space. And, as Dr Alan Fletcher, Revvity’s Senior Vice President, Life Sciences, states “We are very pleased that Celonic has chosen the CHOSOURCE expression platform for their contract development and manufacturing services. Our well-established cGMP manufacturing CHO cell line has over 65 INDs filed globally and empowers companies to accelerate and streamline biotherapeutic development programs from DNA to clinical manufacturing. But what truly differentiates Revvity is our commitment to the evolution of our platforms and ongoing collaboration with our partners to achieve their current, as well as future development and manufacturing needs.”